Janssen Applies For Approval Of New Hepatitis C Drug Simeprevir
This article was originally published in PharmAsia News
Executive Summary
Janssen Pharmaceuticals filed for approval of orally administered simeprevir (TMC435) for the treatment of chronic hepatitis C in Japan on Feb. 22.